Nova filed a NT 10-QSB today.

http://www.sec.gov/Archives/edgar/data/1160078/000116169703000563/nt10q-sep302003.txt

rorosch

Not a word, which I suppose in my opinion is a good thing. I only see the R/S benefiting Hicks and not us shareholders, so not having one is just as good as voting one down, if not better. Just my opinion.

You spelled it wrong as well.

The PR had "Companyies", not "companyes", so I guess it is easy to make a mistake, eh? lol

So did you call Todd? And did you ask him about his spell checker?

farrockaway

"Polyglycoat" - I remember that paint sealant stuff for cars and particularly the stuff they sprayed under the cars to stop rust. Never bought it. lol

I dug this up - the guy who wrote the marketing plan for it and he puts it one his home page, seems proud of it?

"Peter Laitmon has been a marketing and executive sales executive for over thirty years, during which time he has worked in the areas of Consumer products, Communications and Services; both with client and agency.

He has had extensive experience in the marketing of both private and co-label products marketed through traditional and non-traditional channels of distribution, including automobile manufacturers, drug chains and department stores. His background in advertising, merchandising and barter, provides clients with resources for creative choices in distribution and access to many classes of trade.

Laitmon began his career in advertising, where he enjoyed positions at Grey Advertising, and J.Walter Thompson, as well as with Bristol Myers. In 1969, Mr. Laitmon along with a colleague, founded a company which developed the complete Franchise Development package for Sbarro, the Italian Eatery, including what still remains as their current logo. He returned to Sbarro for an assignment as interim Vice President of Marketing in 1995.

In l975, Laitmon wrote the marketing plan for Polyglycoat, the first automotive Paint Sealant and product line to be sold through the New Car Dealer. Beginning with Paint Sealant, Polyglycoat expanded their line to include rust proofing, vinyl top dressing, fabric treatment and undercoating. Polyglycoat enabled the New Car Dealer to make a greater profit when selling these items than they did when selling the car itself. Laitmon is often credited with participating in the formalizing of the Aftermarket at the Automotive Dealership.

Laitmon continues to work with the auto industry in general and to the OEM in particular, where he been representing Meguiar's, (manufacturers of surface care) for almost 20 years. Meguiar's recently made a decision to market select formulations to the furniture industry, and a Henredon/Meguiar's co-label will be introduced this year.

Laitmon also served as a consultant at Jiffy Lube, heading the marketing department prior to the Company being acquired by Pennzoil. He has been an executive with two of the better known companies involved in barter and countertrade, and was also President of a Revco D.S. Division which acquired excess inventories.

Mr. Laitmon is currently the independent distributor of the Vespa Motor Scooter in the Tri State area, which emanated from his roles of the U.S. Representative for Piaggio, the Vespa manufacturer in Italy before then becoming its Director of Marketing and Sales.

Mr. Laitmon resides in Manhattan. He has one son who is an attorney practicing entertainment law in New York City."

http://www.laitmon.com/peter.html

I said it was an interesting read, I didn't make comparisons, nor implied any. I own biotech stocks and one needs a certain, in my opinion, high level of tolerance for those kind of stocks. Risk/reward ratio is usually one one end of the spectrum or the other, in other words feast or famine.

And I am in agreement with the authors conclusion:

"It may be possible that all five companies eventually become highly profitable. This is a big "if", however, and the fact that there are investors willing to take such a big risk on new, publicly-traded stocks is a bearish sign that perhaps risk tolerances have risen too much." (emphasis is mine).

Regarding the concerns and questions directed at Todd Smith, I would suggest talking to him about those. They sound valid and if you are an investor with those concerns then asking him for clarification seems reasonable. Please let us know what he says. Thanks

Have a nice day.

Press Release Source: Nova BioGenetics


Nova BioGenetics Wraps up 10K-SB, Expects to Submit before Deadline
Monday November 10, 2:19 pm ET


ATLANTA--(BUSINESS WIRE)--Nov. 10, 2003--Nova BioGenetics (OTC Bulletin Board: NVBGE - News) announces it is wrapping up its 10K-SB and should file in time for the deadline. Although the company has worked diligently to complete the 10K-SB prior to now, efforts required for the reverse merger delayed the Company's' filing. Additionally, upon completion of the 10K-SB the quarterly filing will follow shortly behind the 10K-SB and will combine the two Companyies as one, since the completion and reverse of the common stock was accomplished after June 30, 2003.
About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed. While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides.

Further information on Nova and its line of products can be found by visiting the company's web site at http://www.NovaBioGenetics.com, Ph.# 770-650-6508, Fax # 770-650-0411, or for investor information, contact Todd Smith, Dir. of Investor Relations and Secretary / Treasurer.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Todd Smith, 770/650-6508
tsmith@novabiogenetics.com



--------------------------------------------------------------------------------
Source: Nova BioGenetics

Press Release Source: Nova BioGenetics


Nova BioGenetics Wraps up 10K-SB, Expects to Submit before Deadline
Monday November 10, 2:19 pm ET


ATLANTA--(BUSINESS WIRE)--Nov. 10, 2003--Nova BioGenetics (OTC Bulletin Board: NVBGE - News) announces it is wrapping up its 10K-SB and should file in time for the deadline. Although the company has worked diligently to complete the 10K-SB prior to now, efforts required for the reverse merger delayed the Company's' filing. Additionally, upon completion of the 10K-SB the quarterly filing will follow shortly behind the 10K-SB and will combine the two Companyies as one, since the completion and reverse of the common stock was accomplished after June 30, 2003.
About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed. While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides.

Further information on Nova and its line of products can be found by visiting the company's web site at http://www.NovaBioGenetics.com, Ph.# 770-650-6508, Fax # 770-650-0411, or for investor information, contact Todd Smith, Dir. of Investor Relations and Secretary / Treasurer.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Todd Smith, 770/650-6508
tsmith@novabiogenetics.com



--------------------------------------------------------------------------------
Source: Nova BioGenetics

wantobe - thanks for remembering to "fry" Janet. Please be so kind as to remember to add EuroStock to the list for next "fryday". The two must be kissing cousins. lol

I've been so busy of late, didn't even notice until now that you changed the name of your board and included other items besides music. Looks like it is doing well. Good luck.

For those of you not familiar with wantobe's board here is a link, he has a talent and I think found his niche here on IHUB.

http://www.investorshub.com/boards/board.asp?board_id=1654

Also in part of my conversation I asked what the main product they were trying to sell, was it AM500? Answer was 3651, here is the spec sheet. Works well for mold remediation.

http://www.bioshield.com/epa/msds_3651_110701.pdf

He essentially said that in the beginning he could see that some one did the "right job" in getting various products licensed and registered with the EPA etc., but that some where down the road management, well, he said "the wheels fell of the wagon". In his time working there he recognizes this and hopes to correct matters. As Sec./Trea. he will be responsible to signing all checks 5K and over. He also verified what I speculated in reading the last PR. Moses is off of the BOD of Nova. I think the board now consists of Todd Smith as Sec./Trea., his father as Jerry Smith as President, Cecil Smith as CEO and I believe Kevin Smith is on the board as well.

Have a nice evening.

LMD

He doesn't have to file the Q. He can let the company go pink, but as I've expressed to him, IMO he'll loose more in the end than gain by allowing that. He knows it would be harder to obtain financing on the pinks than as a reporting entity. If it gets filed, should be some interesting reading, because after all haven't had much to read these days. lol

Take care now, don't stress, if you have kids, do something with them this weekend.

Confucious

His job is to raise the money, while his father has 35 plus years in the pharmaceutical business.

The way I look at it, (and bold the "I") is quite simple.

1. remove Moses from the picture for the most part.
2. bring in new people who have connections to (a) the investment community and (b) the pharmaceutical community.

Will Todd turn things around? I don't know, but given the value of both stocks these days, he can't hurt it much more. lol

I surmise by all the question marks at the end of your post you desire to know a little bit about those awards. If that is the case might I suggest calling him. He is rather easy going on the phone and pleasant to talk to.

Have a nice weekend.

He called me last week, said the auditors were in this week and he hopes to get it out before the 30 days are up. We shall see.

Interesting read:

"Portfolio Strategy - Biotech Bubble

by Charles Rotblut, CFA
Director of Financial Content

Since October 8, there have been five biotech/pharmaceutical IPOs completed, the greatest amount to occur in any four-week period in over two years. What is more remarkable, however, is the fact that the offerings were even completed. Of the five companies, only one is actually selling a product.

Here is a brief description of each offering:

Acusphere {ACUS} has one drug currently in Phase III trials, AI-700. The drug is designed to help identify cardiovascular disease. ACUS has yet to generate any revenues.

Advancis Pharmaceutical {AVNC} develops pulsatile drug products targeted towards the antibiotic market. The company's drugs are designed to release medicine in set intervals, thereby lowering the length of time a patient is required to take antibiotics. AVNC has four drugs in Phase I/II trials and is working on a generic version of Biaxin XL. The company has yet to generate any revenues, but entered into an agreement with GlaxoSmithKline {GSX} that is expected to generate progress payments of $30 million this year.

CancerVax {CNVX} is developing pharmaceutical treatments for cancer. Its most promising drug, Canvaxin, is a treatment for melanoma and is in Phase III trials. CNVX has yet to generate any revenues.

Genitope {GTOP} is also developing treatments for cancer. Its lead candidate, MyVax personalized immunotherapy, is undergoing both Phase III and Phase II trials. GTOP has yet to generate any revenues.

Myogen {MYOG} is developing molecule therapies for cardiovascular disorders. The company has one product being marketed in Europe, Perfan - a treatment for acute decompensated heart failure - and three others in late-stage development. MYOG generated $2.7 million in revenues for the 12-month period ended June 30.

Yes, the total revenues generated by these companies for the 12-month period ending June 30 are less than $3 million. Even more shocking, however, is the market capitalizations assigned to these stocks. The five companies combined are worth nearly $1.3 billion. On a valuation basis, this equates to a price-to-sales ratio of approximately 475.

The general lack of revenues does not even begin to quantify the level of risk involved in these companies. Unlike a technology start-up, biotech and pharmaceutical companies are at the mercy of regulatory agencies. Failure to get approval for their leading drug candidates will likely result in an extended period of time with no revenue being generated. While all drug and biotech companies face the risk of having drug applications being turned down, in the case of ACUS, CNVX, and GTOP, there is no safety net.

So why would companies such as these be able to complete a public offering? Quite simply, there is a large amount of complacency regarding risk. On average, risk tolerances have risen materially since March and many investors do not see the greater willingness to assume risk as worrisome. The result is situations such as this, where a company that should be seeking additional venture capital funding is instead able to turn to the public markets. Good for investment banks, bad for retail investors.

It may be possible that all five companies eventually become highly profitable. This is a big "if", however, and the fact that there are investors willing to take such a big risk on new, publicly-traded stocks is a bearish sign that perhaps risk tolerances have risen too much."

http://www.wallstreetcity.com/commentary/Stocks_full_story.asp?CommentaryID=17674

FarOut

For the most part IHub is calm and clear thinking as compared to Ranging Bull. And I have always sought reasons based upon facts, something once again Raging Bull does not possess, so it is good to hear others asking for same.

I don't have the time this evening to provide a comprehensive answer so I'm just going to touch upon a few things.

First off, I would suggest that if you have questions or concerns regarding Nova to give Todd Smith a call. In my conversations with him I have found him to be forthright and very responsive. However, regarding IBCL he knows little about although he is slowing filling in pieces to the puzzle. You see he is tasked with making Nova a success and not IBCL. But I don't think he will forsake IBCL shareholders because of certain events that did and did not take place in the past.

Nova has until I think 11/15 to file and get the "e" removed and stay on the OTCBB, otherwise it goes pink like IBCL. I think that if Todd Smith can avoid Nova going pink it will go a long way to proving he can turn some things around. We shall see.

It appears right now with the latest SEC filing and PR that TM has been removed from the BOD. The Sec./Trea. position is a BOD position, while sales president is not. So it looks like Nova is pushing him out of the picture. What all that means for IBCL? I don't know.

I'll try and give you a fuller picture when I have more time. Good night.

lol

Also an 8K filing with the SEC today.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): OCTOBER 30, 2003
----------------


NOVA BIOGENETICS, INC.
----------------------------------
(Exact name of registrant as specified in its charter)


DELAWARE 1-16703 58-2618895
- ---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
or incorporation) Number) Identification No.)


8601 DUNWOODY PLACE, SUITE 338, ATLANTA, GEORGIA 30350
------------------------------------------------------------
(Address of principal executive offices, including zip code)


Registrant's telephone number, including area code (770) 650-6508
--------------

HEALTHCARE NETWORK SOLUTIONS, INC.
-------------------------------------------------------------
(Former name or former address, if changed since last report)

<PAGE>

ITEM 5. OTHER IMPORTANT INFORMATION

MANAGEMENT

Our executive officers are as follows after the complete
re-organization of Nova BioGenetics Inc. internal structure.

NAME AGE POSITIONS HELD
---- --- --------------

Dr. Cecil Smith 50 CEO / Interim COB

Jerry Smith 60 President

Todd Smith 37 Secretary Treasurer

SECRETARY/TREASURER - Mr. Todd Smith has replaced Mr. Tim Moses as the
Secretary/Treasurer for the Company effective September 1, 2003. Mr. Smith has
served as a financial advisor and investment banker for the past thirteen years.
Mr. Smith graduated from Auburn University with a bachelor's degree in finance.
Prior to joining Nova Biogenetics Mr. Smith held positions in the brokerage
community most recently as Vice President at Morgan Stanley Dean Witter. In his
thirteen years of brokerage experience Mr. Smith received many awards of
excellence from a variety of institutional investment firms including AIM,
Invesco, ING and Equitable among others. Mr. Smith participated in over twenty
initial public offerings. Mr. Smith joins Nova Biogenetics as director of
investor relations and serves as Secretary/Treasurer.

2
<PAGE>
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

NOVA BIOGENETICS, INC.

Dated: OCTOBER 30, 2003 By: /s/ Dr. Cecil Smith
---------------------------
Dr. Cecil Smith
Chief Executive Officer,
Interim Chairman of the Board

http://www.sec.gov/Archives/edgar/data/1160078/000116169703000532/0001161697-03-000532.txt

Nova issued a PR - Moses is no longer a member of the Board of Directors. Actually I think the entire board should now consist of "Smiths", which should confuse FishyPete all the more. lol Have a Happy Halloween.

Press Release Source: Nova BioGenetics


Nova BioGenetics Announces Todd Smith's Appointment as Secretary and Treasurer, Replacing Tim Moses
Friday October 31, 9:15 am ET


ATLANTA--(BUSINESS WIRE)--Oct. 31, 2003--Nova BioGenetics, (OTC Bulletin Board: NVBG - News) announces that all re-organization and reverse merger documentation has been completed. As of today's date Todd Smith has assumed the responsibilities as the Company's new Secretary / Treasurer replacing Tim Moses. Smith has served as a financial advisor and investment banker for the past thirteen years. Smith graduated form Auburn University with a bachelor's degree in finance. Prior to joining Nova BioGenetics Smith held positions in the brokerage community most recently as Vice President at Morgan Stanley Dean Witter. In his thirteen years of brokerage experience Smith received many awards of excellence from a variety of institutional investment firms including AIM, Invesco, ING, and Equitable among others. Smith participated in over twenty initial public offerings. Smith joins Nova BioGenetics as director of investor relations and serves as Secretary / Treasurer.
Tim Moses will serve as the president of sales of antimicrobial / Biocides Division.

About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.

While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides. Nova currently has contracted with eight (8) specialty chemical representative agencies with over sixty three (63+) sales agents in the U.S. to market its diverse line of products for that division. Continued expansion, particularly in the overseas markets, is part of the company's marketing strategy.

Further information on Nova and its line of products can be found by visiting the company's web site at http://www.novaBioGenetics.com, Ph.# 770-650-6508, Fax # 770-650-0411, or for investor information, contact Todd Smith, Dir. of Investor Relations and Secretary / Treasurer.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Investor Relations
Todd Smith, 770-650-6508
Fax: 770-650-0411
http://www.novaBioGenetics.com



--------------------------------------------------------------------------------
Source: Nova BioGenetics

Press Release Source: Nova BioGenetics


Nova BioGenetics Announces Todd Smith's Appointment as Secretary and Treasurer, Replacing Tim Moses
Friday October 31, 9:15 am ET


ATLANTA--(BUSINESS WIRE)--Oct. 31, 2003--Nova BioGenetics, (OTC Bulletin Board: NVBG - News) announces that all re-organization and reverse merger documentation has been completed. As of today's date Todd Smith has assumed the responsibilities as the Company's new Secretary / Treasurer replacing Tim Moses. Smith has served as a financial advisor and investment banker for the past thirteen years. Smith graduated form Auburn University with a bachelor's degree in finance. Prior to joining Nova BioGenetics Smith held positions in the brokerage community most recently as Vice President at Morgan Stanley Dean Witter. In his thirteen years of brokerage experience Smith received many awards of excellence from a variety of institutional investment firms including AIM, Invesco, ING, and Equitable among others. Smith participated in over twenty initial public offerings. Smith joins Nova BioGenetics as director of investor relations and serves as Secretary / Treasurer.
Tim Moses will serve as the president of sales of antimicrobial / Biocides Division.

About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.

While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides. Nova currently has contracted with eight (8) specialty chemical representative agencies with over sixty three (63+) sales agents in the U.S. to market its diverse line of products for that division. Continued expansion, particularly in the overseas markets, is part of the company's marketing strategy.

Further information on Nova and its line of products can be found by visiting the company's web site at http://www.novaBioGenetics.com, Ph.# 770-650-6508, Fax # 770-650-0411, or for investor information, contact Todd Smith, Dir. of Investor Relations and Secretary / Treasurer.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Investor Relations
Todd Smith, 770-650-6508
Fax: 770-650-0411
http://www.novaBioGenetics.com



--------------------------------------------------------------------------------
Source: Nova BioGenetics

Press Release Source: Nova BioGenetics


Nova BioGenetics Announces Todd Smith's Appointment as Secretary and Treasurer, Replacing Tim Moses
Friday October 31, 9:15 am ET


ATLANTA--(BUSINESS WIRE)--Oct. 31, 2003--Nova BioGenetics, (OTC Bulletin Board: NVBG - News) announces that all re-organization and reverse merger documentation has been completed. As of today's date Todd Smith has assumed the responsibilities as the Company's new Secretary / Treasurer replacing Tim Moses. Smith has served as a financial advisor and investment banker for the past thirteen years. Smith graduated form Auburn University with a bachelor's degree in finance. Prior to joining Nova BioGenetics Smith held positions in the brokerage community most recently as Vice President at Morgan Stanley Dean Witter. In his thirteen years of brokerage experience Smith received many awards of excellence from a variety of institutional investment firms including AIM, Invesco, ING, and Equitable among others. Smith participated in over twenty initial public offerings. Smith joins Nova BioGenetics as director of investor relations and serves as Secretary / Treasurer.
Tim Moses will serve as the president of sales of antimicrobial / Biocides Division.

About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.

While the company is specifically focused on its biopharmaceutical interests and is presently in a development stage, Nova also operates a division within the company that is responsible for the sale of cutting edge patented and EPA approved antimicrobials and biocides. Nova currently has contracted with eight (8) specialty chemical representative agencies with over sixty three (63+) sales agents in the U.S. to market its diverse line of products for that division. Continued expansion, particularly in the overseas markets, is part of the company's marketing strategy.

Further information on Nova and its line of products can be found by visiting the company's web site at http://www.novaBioGenetics.com, Ph.# 770-650-6508, Fax # 770-650-0411, or for investor information, contact Todd Smith, Dir. of Investor Relations and Secretary / Treasurer.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Investor Relations
Todd Smith, 770-650-6508
Fax: 770-650-0411
http://www.novaBioGenetics.com



--------------------------------------------------------------------------------
Source: Nova BioGenetics

jurisper

Wilbur Miles was the transfer agent on BSTI. That is, he is name behind the company:

American Stock Transfer & Trust Company
40 Wall Street
New York, NY 10005
1-800-937-5449


I spoke with him once, he wouldn't provide squat for information, so I called corp. council Gary Wolff and he didn't help that much either, although he did try to get me the info I sought, except then I spoke with the SEC and come to find out I wasn't entitled to the info. Oh well, just tossing the name out there in case you run across it. Thanks for the information.

LMD

"While we await pink" ??????

We are already off of the OTCBB and on the pink sheets.

http://www.investorshub.com/boards/read_msg.asp?message_id=809604

positive - from day one (August 25th 2002) when the site name was bought and registered with NetworkSolutions it has remained the same - Under Construction. I have a tickler system and check it for activity once a month.

utoh

I'm the same way no time to verify. I do recall however, that sishield.com has been that way "under construction" since Villahoz left BioShield in July of 2002. When I last spoke with him about it, some time during the summer of 02, he said it was his intention to get it up and running, well that was over a year ago. But he doesn't have shareholders to listen to. (like that makes a difference) lol

With Nova, my guess is they switched Domain Servers, in other words a new company will be hosting the web site and the data has not been migrated as of yet.

Hey Tyfoon - you're poor grammar is starting to show through, which always happens sooner or later. lol

Ghost - if you paid attention - earlier today I mentioned the site was down and also listed the change in Domain servers. That could be the reason for the site being down.

http://www.investorshub.com/boards/read_msg.asp?message_id=1582663

it appears Nova has changed Domain servers and the site is down. Domain server info from back in August had this:

"Domain servers in listed order:
NS1.RACKSHACK.NET
NS2.RACKSHACK.NET"

http://www.investorshub.com/boards/read_msg.asp?message_id=1367433

And now a review of networksolutions.com's records show these Domain servers:

"Domain servers in listed order:
NS1.MYDOMAIN.COM
NS2.MYDOMAIN.COM"

Far Out

I have never purchased those reports. I have upon occasion been able to get my hands on a free one. They appear to be basically computer generated based upon general information available from the Internet.

Regarding your comments on Anthrax, yes indeed I agree with you. We were all told at the last conference call about the cost to obtain EPA approval and how it was prohibitive. I was told the very same thing by Dr. Villahoz. He indicated TM didn't feel the additional 250K needed to obtain EPA approval was worth the potential return. Same thing holds true for using IBCL products in California. It was too expensive to obtain the necessary regulatory approval requirements that California additionally imposes up a company. If you recall LMD was surprised when he found that out a while back. But at least he didn't call the product fraudulent.

I can certainly understand people being critical of the company, it is important however, to get the facts right, as IMO you have done. Thanks.

Dakota

I'm not sure about the "canned" part, because I haven't verified. I just surmise it to be so because I saw the name removed from the web site. Well that and my conversation with Todd Smith where he indicated if Jim and Jodi aren't selling then it was time to let them go.

My belief that Jim did not fully understand the product comes from conversations with NoMo, Dierdre and e-mails and posts from LMD. Now as far as trying to stretch that into "cahoots with JE", in my opinion goes too far, but I could be wrong. Jim and Jodi came from NALCO when the division they worked for was sold to _____, name escapes me. He should have been fairly knowledgeable about the product(s). And in fact I spoke with him once when he worked for NALCO and he seemed to know his stuff. But then what do I know? lol

Court case - no idea, only snippet of info I recall came from utoh a while back. If I get a chance I'll make a call.

LMD

Let me be more concise. You made the statement:

"Then I find out Anthrax is fraud"

To me, that sentence implies that a particular product that IBCL sells does not kill Anthrax and is fraudulent.

However, when asked to support your statement you talk about:

"The SEC statements claimed there was no such meetings"

Do you realize, that the product's efficacy and whether or not meetings were held "to sell the product" are two different things?

Additionally you are factually incorrect. The meetings took place, what is the issue of contention is the nature of those meetings. In my opinion it is important to get the facts right.

Additionally the 1/29, and 1/30 press releases do not mention Anthrax. The clarification PR on 2/3 states in part:

"IBCI is prepared to discuss everything requested by the agent, including manufacturing capabilities, good laboratory practices and protocols, security of the facility and security of internal data files on Anthrax, including test locations and employee confidentiality, all of which relate to the business operations."

Hence, the only reference I see to Anthrax was the above statement, which I would speculate contains a fair amount of truth, especially if we are to believe the FBI was inquiring about the Anthrax mailings.

From what I read that was submitted to the U.S. Senate committee and my conversations with Dr. Villahoz, I believe the product works against Anthrax. However, I agree that the nature of those meetings with the FBI were different than what we were led to believe. But to me that goes to the heart of the issue about sales or lack there of and not a products efficacy.

In response to this questions of yours:

"What is it you are trying to convince myself and others of?"

My concern is that the facts as best as we know them are presented here so others can make up their own mind. If you post that you believe the Anthrax product is bogus, I will challenge you to support that claim, and that is what I did.

Now regarding a long standing claim of yours with respect to Jim Joyce - where you essentially believe he was wrong and provided you with erroneous information, I tend to agree with your position, not fully, but much more than in the past. I also think the Nova got rid of him, but I don't have the time to verify. If I recall correctly the Nova web site removed his name a couple of weeks ago, but it appears Nova has changed Domain servers and the site is down. Domain server info from back in August had this:

"Domain servers in listed order:
NS1.RACKSHACK.NET
NS2.RACKSHACK.NET"

http://www.investorshub.com/boards/read_msg.asp?message_id=1367433

And now a review of networksolutions.com's records show these Domain servers:

"Domain servers in listed order:
NS1.MYDOMAIN.COM
NS2.MYDOMAIN.COM"

Any way I have to run.

LMD - but you didn't answer the question or support the contention that you made, which was:

"Then I find out Anthrax is fraud"

So how did you find that out - or are you making it up?

If you are going to make such a statement, I would expect you to support your statement. So please enlighten us.

Thank you.

LMD

"Then I find out Anthrax is fraud"

Where did you find this out? Would you please provide your DD to us, or is this just another fabrication of what I would label your over active imagination?

Thanks

Echelon Corporation to Announce Q3 Earnings on October 14th, 2003; ToComply with Federal Regulation FD, Echelon is Providing Notice of QuarterlyEarnings Conference Call

SAN JOSE, Calif., Oct 7, 2003 (BUSINESS WIRE) -- Echelon Corporation (NASDAQ:ELON) will be holding its quarterly earnings conference call for investors and analysts on October 14th, 2003 at 8:00 am ET (5:00 am PT). Echelon is hosting the earnings call at an earlier time to accommodate both market hours and the call hosts, who will be in Munich, Germany attending the LonWorld(R) Exhibition. The earnings announcement itself is scheduled to cross the wire shortly after 7:00 am ET (4:00 am PT). Echelon is sending out this release regarding Q3-2003 only to comply with Federal Regulation FD.

Financial analysts will be notified by fax which toll-free number they should call to access the Q3-2003 conference call. Other interested parties may listen in on the conference call via live Webcast at www.echelon.com. Alternatively, the general public may also access the call at 1-800-388-8975 (callers outside the US please use +1-973-694-2225); however, due to a limited number of available phone lines, the company asks that only those persons without Web access call this number.

About Echelon Corporation

Echelon Corporation is the creator of the LonWorks(R) platform, the world's most widely used standard for connecting everyday devices such as appliances, thermostats, air conditioners, electric meters, and lighting systems to each other and to the Internet. Echelon's hardware and software products enable manufacturers and integrators to create smart devices and systems that lower cost, increase convenience, improve service, and enhance productivity, quality, and safety. Thousands of companies have developed and installed LonWorks products and more than 30 million LonWorks enabled processors have been shipped for use in homes, buildings, factories, trains, and other systems worldwide.

Further information regarding Echelon can be found at www.echelon.com.

Echelon, LonWorks, LonWorld and the Echelon logo are trademarks of Echelon Corporation registered in the United States and other countries.

SOURCE: Echelon Corporation


CONTACT: Echelon Corporation
Steve Nguyen, 408-938-5272 (Press)
qnguyen@echelon.com
Chris Stanfield, 408-938-5243 (Investor Relations)
cstanfield@echelon.com
or
McQUERTER
Tina Wilmott, 858-450-0030 x140 (Press)
twilmott@mcquerter.com

Sonus Networks To Host Conference Call To Discuss Q3 FY2003 FinancialResults

WESTFORD, Mass., Oct 1, 2003 (BUSINESS WIRE) -- Sonus Networks (Nasdaq: SONS) has scheduled a conference call for Wednesday, October 8, 2003, at 4:45 pm Eastern to announce its Q3 FY2003 financial results. Sonus expects to issue its financial results after the close of the market on Wednesday, October 8, 2003.


Date: Wednesday, October 8, 2003
Time: 4:45 pm Eastern

To listen via telephone:
Dial-in number: +1-888-428-4471 or +1-612-288-0329

To listen via the Internet:

Sonus will host a live webcast of the conference call. To access the webcast, visit the Sonus Networks Investor Relations site at www.sonusnet.com.

Replay:

A telephone playback of the call will be available following the conference and can be accessed by calling +1-800-475-6701 or +1-320-365-3844. The access code for the replay is 700338. The telephone playback will be available through Wednesday, October 22, 2003.

The webcast will be available on the Sonus Networks Investor Relations site through Wednesday, October 8, 2004. To access the replay of the webcast, visit the Investor Relations site at www.sonusnet.com.

About Sonus Networks

Sonus Networks, Inc., is a leading provider of packet voice infrastructure solutions for wireline and wireless service providers. With its Open Services Architecture(TM) (OSA), Sonus delivers end-to-end solutions addressing a full range of carrier applications, including trunking, residential access and Centrex, tandem switching, and IP voice termination, as well as enhanced services. Sonus' award-winning voice infrastructure solutions, including media gateways, softswitches and network management systems, are deployed in service provider networks worldwide. Sonus, founded in 1997, is headquartered in Westford, Massachusetts. Additional information on Sonus is available at www.sonusnet.com.

Sonus is a registered trademark of Sonus Networks. Open Services Architecture is a trademark of Sonus Networks. All other trademarks, service marks, registered trademarks, or registered service marks are the property of their respective owners.

SOURCE: Sonus Networks, Inc.


CONTACT: Sonus Networks, Inc.
Jocelyn Philbrook (IR), 978-589-8672
jphilbrook@sonusnet.com
or
Beth Morrissey (MR), 978-589-8579
bmorrissey@sonusnet.com

maidsintheusa.biz

Domain Name: MAIDSINTHEUSA.BIZ
Domain ID: D2113865-BIZ
Sponsoring Registrar: MELBOURNE IT D/B/A INTERNET NAMES WORLD WIDE
Domain Status: ok
Registrant ID: A10083827030193
Registrant Name: MAIDS IN THE USA INC.
Registrant Organization: MAIDS IN THE USA INC.
Registrant Address1: 128 OLD MILL COURT
Registrant City: PONTE VEDRA BEACH
Registrant State/Province: FLORIDA
Registrant Postal Code: 32082
Registrant Country: United States
Registrant Country Code: US
Registrant Phone Number: +1.9042802142
Registrant Email: pboskovit@eathlink.net
Administrative Contact ID: A100838148408295
Administrative Contact Name: PETER BOSKOVITCH
Administrative Contact Organization: PETER BOSKOVITCH
Administrative Contact Address1: 128 OLD MILL COURT
Administrative Contact City: PONTE VEDRA BEACH
Administrative Contact State/Province: FLORIDA
Administrative Contact Postal Code: 32082
Administrative Contact Country: United States
Administrative Contact Country Code: US
Administrative Contact Phone Number: +1.9042802142
Administrative Contact Email: pboskovit@eathlink.net
Billing Contact ID: A100838148408298
Billing Contact Name: peter boskovitch
Billing Contact Organization: maids in the usa inc.
Billing Contact Address1: 128 old mill court
Billing Contact City: ponte vedra beach
Billing Contact State/Province: florida
Billing Contact Postal Code: 32082
Billing Contact Country: United States
Billing Contact Country Code: US
Billing Contact Phone Number: +1.9042802142
Billing Contact Email: pboskovit@earthlink.net
Technical Contact ID: A10083827030191
Technical Contact Name: DNS DoubleDomains.c
Technical Contact Organization: DoubleDomains.com
Technical Contact Address1: PO BOX 23245
Technical Contact City: Chagrin Falls
Technical Contact State/Province: OH
Technical Contact Postal Code: 44023-0245
Technical Contact Country: United States
Technical Contact Country Code: US
Technical Contact Phone Number: +1.0000000000
Technical Contact Email: dns@DoubleDomains.com
Name Server: NS.SUCCESSFULHOSTING.COM
Name Server: NS2.SUCCESSFULHOSTING.COM
Created by Registrar: MELBOURNE IT D/B/A INTERNET NAMES WORLD WIDE
Last Updated by Registrar: MELBOURNE IT D/B/A INTERNET NAMES WORLD WIDE
Domain Registration Date: Sat Dec 15 02:18:25 GMT 2001
Domain Expiration Date: Thu Dec 14 23:59:59 GMT 2006

Thanks Dakota - I just quickly removed all Nova from the Ibox. Later I'll fix it up more.

Kirby

The subject reads:

Fwd: Conversation with Todd Smith

If you are using a SPAM filter the e-mail because it contains "Fwd" might treat it as SPAM, hence I suggest looking in your trash can or turning off all filters.

Anyway I sent it again, let me know.

Kirby

I just forwarded both to you. One from Monday, and the one form last night. Let me know if you get them.

Thanks

Kirby

I suspect so, because sometimes e-mail that includes your name in the "cc" or "bcc" address box gets treated as spam. It becomes a matter of tweaking the settings. However, I see that you are signed up under IBCL but not Nova. I'll forward the last couple of Chair Mails, let me know if you get them. I'll be sending another one later today the regular way and let me know if you get that one. In the mean time you just need to sign up under Nova and the link is on the bottom of the Information Box.

Thanks and take care

Chay

The link is in the lower left corner of the Information Box.

http://www.investorshub.com/boards/chairmail_sub.asp?board_id=1149

I sent out a Chair Mail. (eom)